Rising demand for personalized medications and globalization of clinical trials are the two chief growth drivers in this segment. Besides this, impending patent expiry of blockbuster drugs and emergence of biosimilars have spurred growth prospects in the clinical trials market. However, a lack of clear understanding of biosimilars may make clinical trials a daunting task. Nonetheless, digitization in biomedical research offers lucrative prospects for growth.
Our research studies highlight trends that market players should tap into for sustainable growth. We also identify key hurdles and recommend solutions to overcome them.
Clinical Trials Market Research Reports
Jun, 2016 | 70 pages
Viral conjunctivitis, or “pink-eye”, is a highly contagious infection of the eye, wherein irritation, redness, watery discharge, and photophobia or light sensitivity are common symptoms. Currently, there is no approved treatment for this disease. Therefore, the use of viral conjunctivitis drugs is increasingly becoming mainstream, opening up a broad avenue for these medications. The market for viral conjunctivitis drugs will show an exceptional CAGR of 69.60% during the forecast period 2020-2023, when the projected revenue will reach US$462.4 mn by 2023.
Nov, 2015 | 94 pages
Of late, the demand for non-small cell lung cancer (NSCLC) therapeutics has witnessed a significant surge, globally. The robust rise in the number of patients suffering from NSCLC across the world is likely to strengthen this trend considerably in the near future. The market for NSCLC therapeutics presented a global opportunity worth US$4.9 bn in 2014. Analysts project it to rise at a CAGR of 12.10% during the period from 2015 to 2023 and attain a value of US$15.1 bn by the end of the forecast period.
Sep, 2015 | 155 pages
The world mice model market is envisaged to be primarily advantaged by the growing investments in biomedical research which plays a vital role in pharmaceutical and healthcare sectors. Investment in biomedical research is considered to be a crucial determinant for gauging the level of research and development achieved by a nation. Mice models could attract a decent demand in such investments, which could eventually increase in the near future because of their diversified applications.
Mar, 2015 | 151 pages
The increasing occurrence of adverse drug reaction (ADR) and the rising policies implemented by governments on drug safety regulations globally will fuel the growth of the global pharmacovigilance market. The market for pharmacovigilance has been growing in leaps and bounds owing to the increasing aging population, raising the introduction of new drugs. Furthermore, health regulatory authorities including EMEA and the U.S. FDA are pressurizing on submission of data through electronic mediums. This will also positively impact the growth of the global pharmacovigilance market.
Sep, 2014 | 74 pages
Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms.
Dec, 2012 | 74 pages
The global in-vitro toxicity testing market is projected to reach $2.7 billion by the year 2015 at a compounded annual growth rate of 15% due to the increasing awareness towards animal welfare in laboratory research testing. Cosmetics and personal care industry is currently the largest sectors accounting for more than 50% of the total market share. This sector is valued at $702 million and expected to reach $1.3 billion by 2015 at a CAGR of 13.1%. Pharmaceutical segment is one of the most significant segments of this industry. This segment is expected to grow at the CAGR of 18.2% and reach the market value of $976 million by 2015.
Oct, 2012 | 44 pages
The global chemotherapy-induced nausea and vomiting (CINV) market is expected to reach USD 1.7 billion by 2015, due to prevalent cancer related conditions and subsequent increase in the CINV pool. The global CINV patient pool is estimated to reach 4.6 million by 2015. The Asian region is expected to witness the largest patient share for CINV contributing majorly to the total CINV patient pool thereby presenting a huge potential for the Netupitant - Palonosetron market.